Arcturus Therapeutics Holdings Inc. (ARCT), is a renowned biopharmaceutical company whose mission is to develop novel and innovative medicines to improve the lives and health of people across the globe. Established in 2013, ARCT is headquartered in San Diego, California, and operates with a heavy concentration on the advancement of RNA therapeutics.
RNA therapeutics is a rapidly expanding division of medicine which focuses on the manipulation of RNA (ribonucleic acid) to either disrupt, correct, or replace disease-causing genes. This cutting-edge field has given hope to countless patients suffering from diseases which were once considered untreatable or those lacking effective treatment options.
Arcturus's acclaimed development pipeline includes both partnered and in-house programs. The company has built a substantial global presence through notable partnerships with large pharmaceutical companies like Ultragenyx, Takeda, CureVac, and Janssen Pharmaceuticals.
One of the company's most notable developments is its messenger RNA (mRNA) platforms: LUNAR and STARR. They are created to develop therapeutics for diseases with unmet medical needs, such as genetic, infectious, liver, respiratory diseases, and various types of cancer.
The LUNAR platform, designed to efficiently deliver RNA drugs to targeted tissues by creating lipid-mediated nanoparticles, is considered one of ARCT’s most innovative developments. Meanwhile, the company's STARR Technology is a proprietary RNA delivery platform that combines self-replicating RNA with LUNAR, in a single solution suitable for various types of applications.
In addition to its innovative science, ARCT created headlines with its endeavors during the COVID-19 pandemic. The company developed ARCT-021, a potential vaccine for SARS-CoV-2. The vaccine uses self-transcribing and replicating RNA (STARR™) technology combined with LUNAR®, a leading lipid-mediated delivery system. Clinical trials of the vaccine are underway with initial results showing promise, putting Arcturus Therapeutics at the forefront of the medical research world.
Arcturus Therapeutics continues to lead the field with its ambitious approach to medicine, aspiring to achieve challenging scientific breakthroughs while maintaining its dedication to improving human health. As a company, ARCT is driven by these values and dedicated to meeting the unmet medical needs of patients around the world. This dedication and significant technological advancements, paired with strategic collaborations, have propelled Arcturus Therapeutics to a respected position in the biopharmaceutical industry.